These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20145662)

  • 1. Pediatrics: combining antimuscarinics shows promise for overactive bladder.
    Wyndaele JJ
    Nat Rev Urol; 2010 Feb; 7(2):66-8. PubMed ID: 20145662
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
    Chapple C
    Urologe A; 2007 Apr; 46(4):422, 424-6; author reply 426, 428. PubMed ID: 17384923
    [No Abstract]   [Full Text] [Related]  

  • 3. [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
    Goepel M
    Urologe A; 2006 Jul; 45(7):847-51. PubMed ID: 16816976
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.
    Hart WM; Abrams P; Munro V; Retsa P; Nazir J
    J Med Econ; 2013 Oct; 16(10):1246-54. PubMed ID: 23885660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods].
    Kosilov KV; Loparev SA; Krasnykh MA; Kosilova LV
    Adv Gerontol; 2014; 27(1):149-55. PubMed ID: 25051773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study.
    Akino H; Namiki M; Suzuki K; Fuse H; Kitagawa Y; Miyazawa K; Fujiuchi Y; Yokoyama O
    Int J Urol; 2014 Apr; 21(4):389-94. PubMed ID: 24118296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
    Chapple CR; Rechberger T; Al-Shukri S; Meffan P; Everaert K; Huang M; Ridder A;
    BJU Int; 2004 Feb; 93(3):303-10. PubMed ID: 14764127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic management of overactive bladder.
    Lam S; Hilas O
    Clin Interv Aging; 2007; 2(3):337-45. PubMed ID: 18044184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.
    Chapple CR; Araño P; Bosch JL; De Ridder D; Kramer AE; Ridder AM
    BJU Int; 2004 Jan; 93(1):71-7. PubMed ID: 14678372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.
    Zinner N; Noe L; Rasouliyan L; Marshall T; Seifeldin R
    Curr Med Res Opin; 2008 Jun; 24(6):1583-91. PubMed ID: 18423103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries.
    Milsom I; Axelsen S; Kulseng-Hansen S; Mattiasson A; Nilsson CG; Wickstrøm J
    Acta Obstet Gynecol Scand; 2009; 88(6):693-9. PubMed ID: 19384673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly.
    Ulahannan D; Wagg A
    Clin Interv Aging; 2009; 4():191-6. PubMed ID: 19503781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on drugs for overactive bladder syndrome.
    Drug Ther Bull; 2007 Jun; 45(6):44-8. PubMed ID: 17583229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial comment on: Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?
    Rembratt A
    Eur Urol; 2009 Mar; 55(3):719. PubMed ID: 18584945
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial comment on: Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?
    Porru D
    Eur Urol; 2009 Mar; 55(3):720. PubMed ID: 18584943
    [No Abstract]   [Full Text] [Related]  

  • 17. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
    Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
    Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of anticholinergic medications for overactive bladder symptoms.
    Felicilda-Reynaldo RF
    Medsurg Nurs; 2013; 22(2):119-23. PubMed ID: 23802499
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review.
    Medhi B; Mittal N; Bansal D; Prakash A; Sarangi SC; Nirthi B
    Indian J Physiol Pharmacol; 2013; 57(4):343-53. PubMed ID: 24968572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.
    Chapple CR; Martinez-Garcia R; Selvaggi L; Toozs-Hobson P; Warnack W; Drogendijk T; Wright DM; Bolodeoku J;
    Eur Urol; 2005 Sep; 48(3):464-70. PubMed ID: 15990220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.